↓ Skip to main content

Efficacy of Alteplase in a Mouse Model of Acute Ischemic Stroke

Overview of attention for article published in Stroke, May 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (81st percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

5 tweeters
1 patent
1 Facebook page
1 Wikipedia page


25 Dimensions

Readers on

63 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Efficacy of Alteplase in a Mouse Model of Acute Ischemic Stroke
Published in
Stroke, May 2016
DOI 10.1161/strokeaha.116.012238
Pubmed ID

Cyrille Orset, Benoit Haelewyn, Stuart M. Allan, Saema Ansar, Francesco Campos, Tae Hee Cho, Anne Durand, Mohamad El Amki, Marc Fatar, Isaac Garcia-Yébenes, Maxime Gauberti, Saskia Grudzenski, Ignacio Lizasoain, Eng Lo, Richard Macrez, Isabelle Margaill, Samaneh Maysami, Stephen Meairs, Norbert Nighoghossian, Josune Orbe, Jose Antonio Paramo, Jean-Jacques Parienti, Nancy J. Rothwell, Marina Rubio, Christian Waeber, Alan R. Young, Emmanuel Touzé, Denis Vivien


The debate over the fact that experimental drugs proposed for the treatment of stroke fail in the translation to the clinical situation has attracted considerable attention in the literature. In this context, we present a retrospective pooled analysis of a large data set from preclinical studies, to examine the effects of early versus late administration of intravenous recombinant tissue-type plasminogen activator. We collected data from 26 individual studies from 9 international centers (13 researchers; 716 animals) that compared recombinant tissue-type plasminogen activator with controls, in a unique mouse model of thromboembolic stroke induced by an in situ injection of thrombin into the middle cerebral artery. Studies were classified into early (<3 hours) versus late (≥3 hours) drug administration. Final infarct volumes, assessed by histology or magnetic resonance imaging, were compared in each study, and the absolute differences were pooled in a random-effect meta-analysis. The influence of time of administration was tested. When compared with saline controls, early recombinant tissue-type plasminogen activator administration was associated with a significant benefit (absolute difference, -6.63 mm(3); 95% confidence interval, -9.08 to -4.17; I(2)=76%), whereas late recombinant tissue-type plasminogen activator treatment showed a deleterious effect (+5.06 mm(3); 95% confidence interval, +2.78 to +7.34; I(2)=42%; Pint<0.00001). Results remained unchanged after subgroup analyses. Our results provide the basis needed for the design of future preclinical studies on recanalization therapies using this model of thromboembolic stroke in mice. The power analysis reveals that a multicenter trial would require 123 animals per group instead of 40 for a single-center trial.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 63 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 1 2%
Unknown 62 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 12 19%
Student > Ph. D. Student 7 11%
Student > Bachelor 7 11%
Student > Doctoral Student 4 6%
Other 4 6%
Other 14 22%
Unknown 15 24%
Readers by discipline Count As %
Medicine and Dentistry 14 22%
Neuroscience 13 21%
Biochemistry, Genetics and Molecular Biology 6 10%
Pharmacology, Toxicology and Pharmaceutical Science 5 8%
Agricultural and Biological Sciences 3 5%
Other 7 11%
Unknown 15 24%

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 June 2022.
All research outputs
of 22,860,626 outputs
Outputs from Stroke
of 11,548 outputs
Outputs of similar age
of 298,342 outputs
Outputs of similar age from Stroke
of 136 outputs
Altmetric has tracked 22,860,626 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,548 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.5. This one has gotten more attention than average, scoring higher than 69% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 298,342 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 136 others from the same source and published within six weeks on either side of this one. This one is in the 49th percentile – i.e., 49% of its contemporaries scored the same or lower than it.